β-Lactam Antibiotics Renaissance.

Wenling Qin, Mauro Panunzio, Stefano Biondi
Author Information
  1. Wenling Qin: ISOF-CNR Department of Chemistry "G. Ciamician", Via Selmi, 2 I-40126 Bologna, Italy. wenling.qin2@unibo.it.
  2. Mauro Panunzio: ISOF-CNR Department of Chemistry "G. Ciamician", Via Selmi, 2 I-40126 Bologna, Italy. mauro.panunzio@unibo.it.
  3. Stefano Biondi: Allecra Therapeutics SAS, 13, rue de Village-Neuf, F-68300 St-Louis, France. sdb@allecra.com.

Abstract

Since the 1940s β-lactam antibiotics have been used to treat bacterial infections. However, emergence and dissemination of β-lactam resistance has reached the point where many marketed β-lactams no longer are clinically effective. The increasing prevalence of multidrug-resistant bacteria and the progressive withdrawal of pharmaceutical companies from antibiotic research have evoked a strong reaction from health authorities, who have implemented initiatives to encourage the discovery of new antibacterials. Despite this gloomy scenario, several novel β-lactam antibiotics and β-lactamase inhibitors have recently progressed into clinical trials, and many more such compounds are being investigated. Here we seek to provide highlights of recent developments relating to the discovery of novel β-lactam antibiotics and β-lactamase inhibitors.

Keywords

References

  1. J Antimicrob Chemother. 2006 Nov;58(5):916-29 [PMID: 16997845]
  2. Antimicrob Agents Chemother. 2007 Mar;51(3):826-30 [PMID: 17145788]
  3. Int J Antimicrob Agents. 2007 Nov;30(5):443-5 [PMID: 17644319]
  4. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4849-52 [PMID: 18701284]
  5. Clin Infect Dis. 2009 Jan 1;48(1):1-12 [PMID: 19035777]
  6. Int J Antimicrob Agents. 2009 Nov;34(5):402-6 [PMID: 19428220]
  7. Antimicrob Agents Chemother. 2010 Feb;54(2):846-51 [PMID: 19933793]
  8. Clin Microbiol Infect. 2010 Sep;16(9):1482-7 [PMID: 20002107]
  9. Clin Microbiol Rev. 2010 Jan;23(1):160-201 [PMID: 20065329]
  10. Clin Infect Dis. 2010 Apr 15;50(8):1081-3 [PMID: 20214473]
  11. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302 [PMID: 20308379]
  12. Antimicrob Agents Chemother. 2010 Aug;54(8):3427-31 [PMID: 20457817]
  13. Antimicrob Agents Chemother. 2010 Sep;54(9):3933-7 [PMID: 20547785]
  14. J Antimicrob Chemother. 2010 Sep;65(9):1972-4 [PMID: 20595207]
  15. Clin Infect Dis. 2010 Sep 15;51(6):641-50 [PMID: 20695801]
  16. J Antimicrob Chemother. 2010 Nov;65(11):2376-81 [PMID: 20801783]
  17. Drugs. 2010 Oct 1;70(14):1785-97 [PMID: 20836573]
  18. J Antimicrob Chemother. 2010 Nov;65 Suppl 3:iii25-33 [PMID: 20876625]
  19. Curr Opin Microbiol. 2010 Oct;13(5):551-7 [PMID: 20888287]
  20. Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S51-4 [PMID: 20929371]
  21. Antimicrob Agents Chemother. 2011 Jun;55(6):2992-4 [PMID: 21422208]
  22. Drug Resist Updat. 2011 Apr;14(2):88-94 [PMID: 21439891]
  23. Nature. 2011 Apr 7;472(7341):32 [PMID: 21475175]
  24. J Antimicrob Chemother. 2011 Sep;66(9):1941-4 [PMID: 21700626]
  25. Curr Med Chem. 2011;18(27):4223-36 [PMID: 21838683]
  26. Org Lett. 2011 Oct 21;13(20):5480-3 [PMID: 21916523]
  27. Nat Rev Drug Discov. 2011 Sep 30;10(10):727-8 [PMID: 21959280]
  28. Expert Rev Anti Infect Ther. 2011 Oct;9(10):909-22 [PMID: 21973303]
  29. Antimicrob Agents Chemother. 2012 Jan;56(1):258-70 [PMID: 22024819]
  30. Antimicrob Agents Chemother. 2012 Mar;56(3):1584-7 [PMID: 22203585]
  31. Antimicrob Agents Chemother. 2012 Mar;56(3):1606-8 [PMID: 22214778]
  32. Nat Rev Drug Discov. 2012 Feb 01;11(2):168 [PMID: 22293569]
  33. J Nat Prod. 2012 Mar 23;75(3):311-35 [PMID: 22316239]
  34. Antimicrob Agents Chemother. 2012 Jun;56(6):3395-8 [PMID: 22430958]
  35. Antimicrob Agents Chemother. 2012 Jul;56(7):3753-7 [PMID: 22526311]
  36. Ther Clin Risk Manag. 2012;8:149-56 [PMID: 22547933]
  37. J Antimicrob Chemother. 2012 Oct;67(10):2424-8 [PMID: 22665388]
  38. Antimicrob Agents Chemother. 2012 Sep;56(9):4779-85 [PMID: 22733066]
  39. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8 [PMID: 22753474]
  40. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17448-53 [PMID: 23043117]
  41. J Antimicrob Chemother. 2013 May;68(5):1120-9 [PMID: 23344577]
  42. Ann N Y Acad Sci. 2013 Jan;1277:76-83 [PMID: 23346858]
  43. Ann N Y Acad Sci. 2013 Jan;1277:105-14 [PMID: 23346860]
  44. Antimicrob Agents Chemother. 2013 May;57(5):2095-102 [PMID: 23422914]
  45. Antimicrob Agents Chemother. 2013 Jun;57(6):2496-505 [PMID: 23439634]
  46. Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308 [PMID: 23458769]
  47. J Org Chem. 2013 May 3;78(9):4207-13 [PMID: 23530949]
  48. J Antimicrob Chemother. 2013 Aug;68(8):1825-31 [PMID: 23580564]
  49. Diagn Microbiol Infect Dis. 2013 Jul;76(3):347-51 [PMID: 23623385]
  50. Antimicrob Agents Chemother. 2013 Jul;57(7):3299-306 [PMID: 23650162]
  51. J Biol Chem. 2013 Sep 27;288(39):27960-71 [PMID: 23913691]
  52. J Antibiot (Tokyo). 2013 Oct;66(10):571-91 [PMID: 24002361]
  53. Org Lett. 2014 Jan 3;16(1):174-7 [PMID: 24329136]
  54. Org Lett. 2014 Jan 17;16(2):480-3 [PMID: 24341538]
  55. Antimicrob Agents Chemother. 2014;58(4):1835-46 [PMID: 24379206]
  56. Core Evid. 2014 Jan 24;9:13-25 [PMID: 24493994]
  57. Antibiotics (Basel). 2013 Dec 06;2(4):500-34 [PMID: 27029317]
  58. Drugs. 1985 Feb;29(2):105-61 [PMID: 3884319]

Word Cloud

Created with Highcharts 10.0.0β-lactamantibioticsβ-lactamaseinhibitorsbacterialinfectionsmanydiscoverynovelSince1940susedtreatHoweveremergencedisseminationresistancereachedpointmarketedβ-lactamslongerclinicallyeffectiveincreasingprevalencemultidrug-resistantbacteriaprogressivewithdrawalpharmaceuticalcompaniesantibioticresearchevokedstrongreactionhealthauthoritiesimplementedinitiativesencouragenewantibacterialsDespitegloomyscenarioseveralrecentlyprogressedclinicaltrialscompoundsinvestigatedseekprovidehighlightsrecentdevelopmentsrelatingβ-LactamAntibioticsRenaissance

Similar Articles

Cited By (13)